← Leaderboards
Douglas Hanahan
University Of California San Francisco
$19,892,030
Attributed
$21,222,919
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–12$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$21,222,919 · 9
By mechanism
R01$14,624,137 · 6
U01$2,933,094 · 1
R37$2,212,700 · 1
P01$1,452,988 · 1
Top collaborators
- Gabriele Bergers5 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Joe W. Gray$35,260,197
- Gabriele Bergers$9,922,926
- Gordon B. Mills$27,749,983
- Donna G Albertson$14,886,713
- Linda Pfiffner$5,544,445
Others in their field
Top investigators on “Angiogenesis”
- David Heimbrook · Leidos Biomedical Research, Inc.$75,067,502
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,567,306
- Martin Friedlander · Scripps Research Institute$48,350,175
- Larry Arthur$33,866,306
- Michael Simons · Yale University$30,647,106
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$29,372,588
Research focus
AngiogenesisMouse ModelIslets Of LangerhansMalignant NeoplasmsTumorLaboratory MouseBaseApoptosisCarcinomaTumor GrowthStagingSignal TransductionEngineeringMediatingPancreasPhenotypeGenetically Modified AnimalsCarcinogenesisGene ExpressionGenetically Engineered MouseBlood VesselsLesionSiteTumor Progression
Grant awards (46)
Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs$526,187
R01 · FY2012 · CA
Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs$526,188
R01 · FY2011 · CA
Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs$542,459
R01 · FY2010 · CA
Mechanisms & Therapeutic Targeting of the Microenvironment in Pancreatic Cancer$307,397
P01 · FY2010 · CA · contact PI
Detecting cancer early with targeted nano-probes for vascular signatures$615,856
R01 · FY2009 · CA · contact PI
Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs$541,356
R01 · FY2009 · CA · contact PI
Regulating invasion in pancreatic tumorigenesis$520,783
R01 · FY2009 · CA · contact PI
Mechanisms & Therapeutic Targeting of the Microenvironment in Pancreatic Cancer$302,018
P01 · FY2009 · CA · contact PI
Functions in tumors of recurrently amplified Prefoldin-4$283,709
R01 · FY2009 · CA · contact PI
Detecting cancer early with targeted nano-probes for vascular signatures$609,536
R01 · FY2008 · CA · contact PI
Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs$525,588
R01 · FY2008 · CA · contact PI
Regulating invasion in pancreatic tumorigenesis$505,613
R01 · FY2008 · CA · contact PI
Immune Enhancement and Therapy of Cancer$500,932
U01 · FY2008 · CA · contact PI
Mechanisms & Therapeutic Targeting of the Microenvironment in Pancreatic Cancer$293,541
P01 · FY2008 · CA · contact PI
Functions in tumors of recurrently amplified Prefoldin-4$283,709
R01 · FY2008 · CA · contact PI
Detecting cancer early with targeted nano-probes for vascular signatures$615,218
R01 · FY2007 · CA · contact PI
Immune Enhancement and Therapy of Cancer$598,634
U01 · FY2007 · CA · contact PI
Stage- & cell-specific targeting of RTK in tumorigenesis$503,750
R01 · FY2007 · CA · contact PI
Regulating invasion in pancreatic tumorigenesis$500,608
R01 · FY2007 · CA · contact PI
Mechanisms & Therapeutic Targeting of the Microenvironment in Pancreatic Cancer$290,661
P01 · FY2007 · CA · contact PI
Functions in tumors of recurrently amplified Prefoldin-4$283,709
R01 · FY2007 · CA · contact PI
Immune Enhancement and Therapy of Cancer$660,725
U01 · FY2006 · CA · contact PI
Detecting cancer early with targeted nano-probes for va*$626,605
R01 · FY2006 · CA · contact PI
Stage- & cell-specific targeting of RTK in tumorigenesis$503,687
R01 · FY2006 · CA · contact PI
Regulating invasion in pancreatic tumorigenesis$500,542
R01 · FY2006 · CA · contact PI
Functions in tumors of recurrently amplified Prefoldin-4$292,182
R01 · FY2006 · CA · contact PI
Mechanisms & Therapeutic Targeting of the Microenvironment in Pancreatic Cancer$259,371
P01 · FY2006 · CA · contact PI
Detecting cancer early with targeted nano-probes$650,000
R01 · FY2005 · CA
Immune Enhancement and Therapy of Cancer$630,621
U01 · FY2005 · CA
Stage- &cell-specific targeting of RTK in tumorigenesis$500,785
R01 · FY2005 · CA
Regulating invasion in pancreatic tumorigenesis$497,656
R01 · FY2005 · CA
Functions in tumors of recurrently amplified Prefoldin-4$299,213
R01 · FY2005 · CA
Immune Enhancement and Therapy of Cancer$542,182
U01 · FY2004 · CA
Stage- &cell-specific targeting of RTK in tumorigenesis$486,199
R01 · FY2004 · CA
Targeted Oncogenesis and Diabetes$474,681
R37 · FY2004 · CA
Stage- &cell-specific targeting of RTK in tumorigenesis$483,260
R01 · FY2003 · CA
Targeted Oncogenesis and Diabetes$460,095
R37 · FY2003 · CA
GENOMICS OF APOPTOSIS &ANGIOGENESIS IN ISLET CARCINOMA$509,669
R01 · FY2002 · CA
Targeted Oncogenesis and Diabetes$450,372
R37 · FY2002 · CA
GENOMICS OF APOPTOSIS &ANGIOGENESIS IN ISLET CARCINOMA$495,396
R01 · FY2001 · CA
MALIGNANT PROGRESSION IN PAPILLOMAVIRUS TRANSGENIC MICE$480,609
R01 · FY2001 · CA
TARGETED ONCOGENESIS AND DIABETES$382,447
R37 · FY2001 · CA
GENOMICS OF APOPTOSIS &ANGIOGENESIS IN ISLET CARCINOMA$468,795
R01 · FY2000 · CA
MALIGNANT PROGRESSION IN PAPILLOMAVIRUS TRANSGENIC MICE$445,270
R01 · FY2000 · CA
TARGETED ONCOGENESIS AND DIABETES$371,357
R37 · FY2000 · CA
TARGETED ONCOGENESIS AND DIABETES$73,748
R37 · FY2000 · CA